- Home
- TTRX vs CNTB Comparison
TTRX vs CNTB Comparison
Compare TTRX & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TTRX | CNTB |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.0M | 128.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | TTRX | CNTB |
|---|---|---|
| Price | $3.42 | $2.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $8.00 | ★ $8.67 |
| AVG Volume (30 Days) | 28.9K | ★ 435.0K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.57 | $0.70 |
| 52 Week High | $5.98 | $3.82 |
Technical Indicators
Market Signals| Indicator | TTRX | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 46.47 | 42.12 |
| Support Level | $2.98 | $2.50 |
| Resistance Level | $3.69 | $2.97 |
| Average True Range (ATR) | 0.26 | 0.26 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 51.07 | 5.47 |
Price Performance
Historical ComparisonAbout TTRX Turn Therapeutics Inc.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.